Objective To compare the short- and long-term outcomes of radiofrequency ablation (RFA) versus liver resection and chemotherapy for liver metastases from gastric cancer. Methods We retrospectively evaluated 50 patients who underwent curative gastrectomy and local treatments for liver metastases (RFA, n?=?20; liver resection, n?=?20; and chemotherapy, n?=?10) from 2008 to 2018. Results The short- and long-term outcomes of each local treatment were evaluated. The median overall survival (OS) after RFA was similar to that after liver resection (20 vs. 20 months, respectively) and longer than that after chemotherapy (20 vs. 10 months, respectively). The 3-year OS and progression-free survival (PFS) rates after RFA were 20% and 10%, respectively, while those in the liver resection group were 23.5% and 23.5%, respectively. The 3-year OS rate after chemotherapy was 10%. The size and number of metastases were prognostic factors for patients with gastric cancer with liver metastasis without statistical significance. Conclusions Among patients with liver metastasis from gastric cancer, OS and PFS were satisfactory and comparable between RFA and liver resection but better than those of chemotherapy. RFA is an appropriate option for patients with gastric cancer who have a solitary liver metastasis measuring ≤3.0?cm.
展开▼
机译：目的比较射频消融（RFA）对胃癌肝转移和化疗的短期和长期结果。方法方法回顾性评估了50例接受肝转移症和局部治疗的50例肝转移（RFA，N？20;肝切除，N？= 20;和化疗，N？=？10）从2008年到2018年。结果评估每种局部治疗的短期和长期结果。 RFA后的中位整体存活（OS）与肝切除（分别为20个月20个月）和比化疗后的长度（分别为20个月）。 RFA后的3年OS和无进展生存率（PFS）率分别为20％和10％，而肝切除组中的那些分别为23.5％和23.5％。化疗后的3年的OS率为10％。转移的大小和数量是胃癌患者具有肝脏转移的患者的预后因素，而无需统计显着性。结论来自胃癌的肝脏转移患者，OS和PFS患者令人满意，RFA和肝切除术比化疗更好。 RFA is an appropriate option for patients with gastric cancer who have a solitary liver metastasis measuring ≤3.0?cm.
展开▼
